IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy
IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy
IAMA to Present Data at American Epilepsy Society 2023 Annual Meeting
IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec
IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe Forum
GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced a partnership with The Sapienza University of Rome, Italy. The planned translational study aims at investigating the functional efficacy of selective chloride modulators in reducing neuronal excitability and hippocampal activity in human tissue from patients with epilepsies and neurodevelopmental disorders, including Dravet syndrome, Focal Cortical Dysplasia, and Rett syndrome.
GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced that Andrea Malizia, Chief Executive Officer, will present at the BIO International Convention, taking place June 5-8, 2023, in Boston, MA.
GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of children affected by brain disorders, today announced the addition of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to its Scientific Advisory Board.
PsychoGenics has signed on with Italy's Iama Therapeutics to run a preclinical study as part of an effort to identify and develop drug candidates to treat Dravet syndrome.
IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome